{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:41:03Z","timestamp":1772804463030,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,5,13]],"date-time":"2014-05-13T00:00:00Z","timestamp":1399939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00228-014-1690-1","type":"journal-article","created":{"date-parts":[[2014,5,12]],"date-time":"2014-05-12T03:23:43Z","timestamp":1399865023000},"page":"941-946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China"],"prefix":"10.1007","volume":"70","author":[{"given":"Ying","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-ya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,13]]},"reference":[{"issue":"1","key":"1690_CR1","first-page":"S48","volume":"12","author":"JM Pellock","year":"2007","unstructured":"Pellock JM (2007) Overview of lamotrigine and the new antiepileptic drugs: the challenge. J Child Neurol 12(1):S48\u2013S52","journal-title":"J Child Neurol"},{"key":"1690_CR2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","volume":"45","author":"SI Johannessen","year":"2006","unstructured":"Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 45:1061\u20131075","journal-title":"Clin Pharmacokinet"},{"key":"1690_CR3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.5414\/CPP47752","volume":"47","author":"JR Milovanovic","year":"2009","unstructured":"Milovanovic JR, Jankovic SM (2009) Population pharmacokinetics of lamotrigine in patients with epilepsy. Int J Clin Pharmacol Ther 47:752\u2013760","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1690_CR4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/0091270007313391","volume":"48","author":"B Punyawudho","year":"2008","unstructured":"Punyawudho B, Ramsay RE, Macias FM, Rowan AJ, Collins JF, Brundage RC, Birnbaum AK (2008) Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 48:455\u2013463","journal-title":"J Clin Pharmacol"},{"key":"1690_CR5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/FTD.0b013e31817fd4d4","volume":"30","author":"N Rivas","year":"2008","unstructured":"Rivas N, Buelga DS, Elger CE, Santos-Borbujo J, Otero MJ, Dominguez-Gil A, Garcia MJ (2008) Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 30:483\u2013489","journal-title":"Ther Drug Monit"},{"key":"1690_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2011.01.016","volume":"95","author":"MI Gulcebi","year":"2011","unstructured":"Gulcebi MI, Ozkaynakci A, Goren MZ, Aker RG, Ozkara C, Onat FY (2011) The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. Epilepsy Res 95:1\u20138","journal-title":"Epilepsy Res"},{"key":"1690_CR7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/WCO.0b013e328328f276","volume":"2","author":"D Franciotta","year":"2009","unstructured":"Franciotta D, Kwan P, Perucca E (2009) Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2:144\u2013149","journal-title":"Curr Opin Neurol"},{"issue":"12","key":"1690_CR8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/FPC.0b013e3283331637","volume":"19","author":"MO Benoit-Binomics","year":"2009","unstructured":"Benoit-Binomics MO, Adam JP, Bernard O et al (2009) A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenet Genomics 19(12):945\u2013954","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"1690_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/FTD.0b013e3181633824","volume":"30","author":"SS Yea","year":"2008","unstructured":"Yea SS, Lee SS, Kim WY, Liu KH, Kim H, Shon JH, Cha IJ, Shin JG (2008) Genetic variations and haplotypes of UDP-glucuronosyltransferase 1A locus in a Korean population. Ther Drug Monit 30(1):23\u201334","journal-title":"Ther Drug Monit"},{"issue":"7","key":"1690_CR10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/humu.9432","volume":"27","author":"SS Thomas","year":"2006","unstructured":"Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J (2006) Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat 27(7):717","journal-title":"Hum Mutat"},{"issue":"7","key":"1690_CR11","doi-asserted-by":"crossref","first-page":"7763","DOI":"10.1007\/s11033-012-1615-y","volume":"39","author":"N Hakooz","year":"2012","unstructured":"Hakooz N, Alzubiedi S, Yousef AM, Arafat T, Dajani R, Ababneh N, Ismail S (2012) UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population. Mol Biol Rep 39(7):7763\u20137768","journal-title":"Mol Biol Rep"},{"key":"1690_CR12","doi-asserted-by":"crossref","unstructured":"Engel J Jr (2001) A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 42(6):796\u2013803","DOI":"10.1046\/j.1528-1157.2001.10401.x"},{"key":"1690_CR13","first-page":"609","volume-title":"Surgical treatment of the epilepsies","author":"J Engel Jr","year":"1993","unstructured":"Engel J Jr, Van Ness PC, Rasmussen TB, Ojemann LM (1993) Outcome with respect to epileptic seizures. In: Engel J Jr (ed) Surgical treatment of the epilepsies, 2nd edn. Raven Press, New York, pp 609\u2013621","edition":"2"},{"key":"1690_CR14","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","volume":"34","author":"A Rowland","year":"2006","unstructured":"Rowland A, Elliot DJ, Williams JA et al (2006) In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interation. Drug Metab Dispos 34:1055\u20131062","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1690_CR15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0090-9556(24)15257-9","volume":"27","author":"A Hiller","year":"1999","unstructured":"Hiller A, Nguyen N, Strassburg CP et al (1999) Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 27(5):605\u2013612","journal-title":"Drug Metab Dispos"},{"key":"1690_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2125.1989.tb03514.x","volume":"28","author":"J Posner","year":"1989","unstructured":"Posner J, Cohen AF, Land G et al (1989) The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinemia (Gilbert\u2019s syndrome). Br J Clin Pharmacol 28:117\u2013120","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1690_CR17","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1124\/mol.107.037952","volume":"72","author":"T Kubota","year":"2007","unstructured":"Kubota T, Lewis BC, Elliot DJ et al (2007) Critical roles of residues 36 and 40 in the phenol and tertiary amine aglycone substrate selectivities of UDP-glucuronosyltransferases 1A3 and 1A4. Mol Pharmacol 72(4):1054\u20131062","journal-title":"Mol Pharmacol"},{"issue":"6","key":"1690_CR18","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00228-012-1449-5","volume":"69","author":"N Singkham","year":"2013","unstructured":"Singkham N, Towanabut S, Lertkachatarn S et al (2013) Influence of the UGT 2B7-161C\u2009>\u2009T polymorphism on the population pharmacokinetics of lamotrigine in Thai patients. Eur J Clin Pharmacol 69(6):1285\u20131291","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"1690_CR19","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/hep.20131","volume":"39","author":"U Ehmer","year":"2004","unstructured":"Ehmer U, Vogel A, Schutte JK, Krone B, Manns MP, Sttassburg CP (2004) Variation of hepatic glucuronidation:novel functional polymorphisms of the UDP glucuronosyltransferase UGT1A4. Hepatology 39(4):970\u2013977","journal-title":"Hepatology"},{"issue":"1","key":"1690_CR20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/dmd.32.1.72","volume":"32","author":"D Wiener","year":"2004","unstructured":"Wiener D, Doerge DR, Fang JL et al (2004) Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver:importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32(1):72\u201379","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1690_CR21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1124\/dmd.104.002576","volume":"33","author":"A Mori","year":"2005","unstructured":"Mori A, Maruo Y, Iwai M, Sato H, Takeuchi Y (2005) UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos 33(5):672\u2013675","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1690_CR22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2133\/dmpk.20.144","volume":"20","author":"M Saeki","year":"2005","unstructured":"Saeki M, Saito Y, Jinno H et al (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20(2):144\u2013151","journal-title":"Drug Metab Pharmacokinet"},{"key":"1690_CR23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/FPC.0b013e328354026b","volume":"22","author":"KK Erickson-Ridout","year":"2012","unstructured":"Erickson-Ridout KK, Sun D, Lazarus P (2012) Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine potential importance of the UGT1A1 A(TA)7TAA and UGT1A4 L48V polymorphisms. Pharmacogenet Genomics 22:561\u2013576","journal-title":"Pharmacogenet Genomics"},{"key":"1690_CR24","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00228-009-0783-8","volume":"66","author":"R Ghotbi","year":"2010","unstructured":"Ghotbi R, Mannheimer B, Aklillu E, Suda A et al (2010) Carriers of the UGT1A4 142\u00a0T\u2009>\u2009G gene variant are predisposed to reduced olanzapine exposure\u2014an impact similar to male gender or smoking in schizophrenic patients. Eur J Pharmacol 66:465\u2013474","journal-title":"Eur J Pharmacol"},{"issue":"R50","key":"1690_CR25","first-page":"1","volume":"8","author":"D Sun","year":"2006","unstructured":"Sun D, Chen G, Dellinger RW, Duncan K et al (2006) Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Can Res 8(R50):1\u201311","journal-title":"Breast Can Res"},{"issue":"2","key":"1690_CR26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2133\/dmpk.20.144","volume":"20","author":"M Saeki","year":"2005","unstructured":"Saeki M, Saito Y, Jinno H et al (2005) Genetic variations and haplotypes of UGT1A4 in a Japanese population. Drug Metab Pharmacokinet 20(2):144\u2013151","journal-title":"Drug Metab Pharmacokinet"},{"key":"1690_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/hmg\/ddg055","volume":"12","author":"JB Duan","year":"2003","unstructured":"Duan JB, Wainwright MS, Comeron JM et al (2003) Synonymous mutations in the human dopamine receptor D2(DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12:205\u2013216","journal-title":"Hum Mol Genet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-014-1690-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-014-1690-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T21:47:44Z","timestamp":1746222464000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-014-1690-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,13]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["1690"],"URL":"https:\/\/doi.org\/10.1007\/s00228-014-1690-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,13]]}}}